Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Genelux Corporation - Common Stock (NQ: GNLX ) 2.930 +0.020 (+0.69%) Streaming Delayed Price Updated: 4:00 PM EST, Nov 8, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Press Releases about Genelux Corporation - Common Stock Genelux Corporation to Participate in Fireside Chat at the Guggenheim Inaugural Healthcare Innovation Conference November 06, 2024 From Genelux Corporation Via GlobeNewswire Genelux Corporation Announces First Patient Dosed in Phase 2 Trial Evaluating Systemic Therapy with Olvi-Vec in Non-Small Cell Lung Cancer October 22, 2024 From Genelux Corporation Via GlobeNewswire Genelux Corporation to Participate in the 2024 Maxim Healthcare Virtual Summit October 09, 2024 From Genelux Corporation Via GlobeNewswire Genelux Corporation to Present at the H.C. Wainwright Global Investment Conference September 03, 2024 From Genelux Corporation Via GlobeNewswire Genelux Corporation Reports Second Quarter 2024 Financial Results and Provides General Business Updates August 14, 2024 From Genelux Corporation Via GlobeNewswire Genelux Corporation to Participate in Fireside Chat at BTIG’s Virtual Biotechnology Conference 2024 July 30, 2024 From Genelux Corporation Via GlobeNewswire Genelux Corporation Announces Pricing of Approximately $27.5 Million Underwritten Offering of Common Stock and Accompanying Warrants May 24, 2024 From Genelux Corporation Via GlobeNewswire Genelux Corporation Announces Proposed Public Offering of Common Stock and Warrants May 23, 2024 From Genelux Corporation Via GlobeNewswire Genelux Corporation Reports First Quarter 2024 Financial Results and Provides General Business Updates May 09, 2024 From Genelux Corporation Via GlobeNewswire Genelux Corporation Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update April 01, 2024 From Genelux Corporation Via GlobeNewswire Genelux Corporation Receives FDA Fast Track Designation for Olvi-Vec in Platinum Resistant/Refractory Ovarian Cancer November 27, 2023 From Genelux Corporation Via GlobeNewswire Genelux Corporation Reports Third Quarter 2023 Financial Results and Provides General Business Updates November 14, 2023 From Genelux Corporation Via GlobeNewswire Young Adults and Pancreatic Cancer: What the 80% Rise in Diagnoses Means for Future Treatment October 11, 2023 EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:GNLX),(NASDAQ:CRNX),(NYSE:PFE),(NASDAQ:SGEN) EQNX::TICKER_END Via FinancialNewsMedia Genelux Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) September 14, 2023 From Genelux Corporation Via GlobeNewswire Genelux Corporation to Present at the H.C. Wainwright Global Investment Conference September 07, 2023 From Genelux Corporation Via GlobeNewswire Genelux Corporation Announces New Chief Financial Officer August 28, 2023 From Genelux Corporation Via GlobeNewswire Genelux Corporation Reports Second Quarter 2023 Financial Results and Provides General Business Updates August 14, 2023 From Genelux Corporation Via GlobeNewswire Genelux Corporation to Participate in Fireside Chat at BTIG’s Virtual Biotechnology Conference 2023 August 02, 2023 From Genelux Corporation Via GlobeNewswire Genelux Corporation Strengthens Senior Management and Clinical Team with Promotions and New Hires July 20, 2023 From Genelux Corporation Via GlobeNewswire Genelux Corporation Announces Publication of Phase I Trial Results of Intrapleural Administration of Olvi-Vec in Patients with Malignant Pleural Effusion from Mesothelioma, Lung or Breast Cancers in Frontiers in Immunology July 10, 2023 From Genelux Corporation Via GlobeNewswire Genelux Corporation and TVAX Biomedical, Inc. announce the issuance of a United States patent covering the combination of an adoptive T cell therapy/oncolytic viral cancer treatment that is exclusively licensed to V2ACT Therapeutics™, LLC June 29, 2023 From Genelux Corporation Via GlobeNewswire Genelux Corporation Set to Join the Russell 3000® and Russell 2000® Indexes Effective June 26, 2023 June 22, 2023 From Genelux Corporation Via GlobeNewswire Genelux Corporation Announces $18 Million Private Placement June 12, 2023 From Genelux Corporation Via GlobeNewswire Genelux Corporation Announces Publication of Positive Topline Data from Phase 2 VIRO-15 Trial Evaluating Olvimulogene Nanivacirepvec (Olvi-Vec) in Platinum-Resistant or Refractory Ovarian Cancer in the Journal of the American Medical Association (JAMA) May 25, 2023 From Genelux Corporation Via GlobeNewswire Genelux Corporation Announces $33 Million Private Placement May 15, 2023 From Genelux Corporation Via GlobeNewswire Genelux Corporation to Ring Nasdaq Opening Bell on March 29, 2023 March 23, 2023 From Genelux Corporation Via GlobeNewswire Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
